Antipsychotics, antidepressants and lithium
The receptor pharmacology of antipsychotic drugs and the dopamine pathways that explain their adverse effects, the classes of antidepressant and their mechanisms, the pharmacology of lithium and why its margin is narrow, and the mechanisms behind the syndromes these drugs cause: extrapyramidal effects, neuroleptic malignant syndrome and serotonin toxicity.
By the end of this page you should be able to
- Describe the receptor actions of typical and atypical antipsychotics and relate them to the four dopamine pathways.
- Describe the extrapyramidal syndromes and their mechanisms and time courses.
- Classify antidepressants by mechanism and describe their characteristic adverse effects.
- Describe the pharmacology of lithium, including its kinetics, interactions and toxicity.
- Distinguish neuroleptic malignant syndrome from serotonin toxicity and from other hyperthermic states.
- Explain the mechanisms of cardiovascular toxicity of these drug groups.
Antipsychotics
All antipsychotic drugs block dopamine D2 receptors, and the therapeutic effect on positive psychotic symptoms correlates with occupancy in the mesolimbic pathway. The trouble is that the same receptor is blocked in three other pathways: the nigrostriatal (producing extrapyramidal effects), the tuberoinfundibular (removing dopamine inhibition of prolactin release, so prolactin rises, with galactorrhoea, amenorrhoea and sexual dysfunction) and the mesocortical (where blockade may worsen negative and cognitive symptoms).
Typical (first generation) agents are grouped by potency. High potency agents such as haloperidol are strongly D2 selective, so extrapyramidal effects dominate and sedation and hypotension are less. Low potency agents such as chlorpromazine block many other receptors, so sedation, antimuscarinic effects and postural hypotension dominate while extrapyramidal effects are fewer.
Atypical (second generation) agents combine D2 with substantial 5-HT2A blockade and often bind D2 more loosely, which reduces extrapyramidal effects and prolactin elevation, at the cost of metabolic harm: weight gain, dyslipidaemia and diabetes, mediated largely by H1 and 5-HT2C blockade. Specific agents have distinctive problems worth knowing: clozapine is reserved for resistant illness because of agranulocytosis (hence mandatory monitoring), myocarditis, seizures, profound constipation with ileus, hypersalivation and marked metabolic effects; quetiapine is highly sedating with prominent postural hypotension; risperidone is the most prolactin-raising of the group; olanzapine causes the most weight gain; and aripiprazole is a partial agonist, so it behaves as a functional antagonist where dopamine is high and an agonist where it is low, producing akathisia more than parkinsonism.
The antiemetic phenothiazines and metoclopramide share D2 blockade, which is why they cause the same extrapyramidal effects, particularly dystonia in young people.
The extrapyramidal syndromes
- Acute dystonia: sustained involuntary muscle contraction, often of neck, jaw, tongue or eyes (oculogyric crisis), within hours to days. More common in young men and with high potency agents. The mechanism is an imbalance between dopaminergic and cholinergic activity in the striatum, which is why an antimuscarinic such as benztropine, or an antihistamine with antimuscarinic activity, relieves it rapidly. Laryngeal dystonia is the dangerous form.
- Akathisia: inner restlessness with an inability to keep still, within days to weeks; easily mistaken for worsening agitation, so the drug is increased and it worsens.
- Parkinsonism: bradykinesia, rigidity and tremor over weeks, from nigrostriatal blockade; it looks like Parkinson disease but is symmetrical more often.
- Tardive dyskinesia: choreoathetoid movements, classically orofacial, after months to years, thought to involve dopamine receptor upregulation and supersensitivity. It may be irreversible and can worsen when the drug is stopped, so it is a reason for using the lowest effective exposure.
- Neuroleptic malignant syndrome is the severe end: see below.
Antidepressants
- Selective serotonin reuptake inhibitors: block the serotonin transporter. Adverse effects: nausea, insomnia or sedation, agitation early in treatment, sexual dysfunction, hyponatraemia from inappropriate antidiuretic hormone secretion (especially in the elderly), increased bleeding risk through platelet serotonin depletion, and serotonin toxicity in combination with other serotonergic drugs. They are relatively safe in overdose but are not free of cardiac effects: citalopram prolongs the QT interval. A discontinuation syndrome with dizziness, paraesthesia, agitation and flu-like symptoms follows abrupt cessation, particularly with short half-life agents; fluoxetine, with its long half-life and active metabolite, is the exception.
- Serotonin and noradrenaline reuptake inhibitors (venlafaxine, duloxetine) add noradrenergic effects: raised blood pressure and heart rate, sweating and tremor; they are also used for neuropathic pain.
- Tricyclic antidepressants inhibit serotonin and noradrenaline reuptake but also block muscarinic, histamine H1, alpha-1 and, importantly in overdose, cardiac sodium and potassium channels. Hence the therapeutic effects come with dry mouth, retention, constipation, blurred vision, delirium, sedation, weight gain and postural hypotension, and in toxicity with QRS widening, QT prolongation, arrhythmia, seizures and hypotension. Sodium bicarbonate is used in toxicity to overcome the sodium channel blockade through sodium loading and alkalinisation; follow local toxicology guidance.
- Monoamine oxidase inhibitors: irreversible non-selective agents prevent breakdown of monoamines, so they cause a hypertensive crisis with tyramine-containing food (which can no longer be deaminated in the gut and displaces stored noradrenaline) and with indirect sympathomimetics, and serotonin toxicity with serotonergic drugs including pethidine, tramadol, fentanyl, dextromethorphan and linezolid. The interaction risk persists for about two weeks after stopping because the enzyme must be resynthesised. Moclobemide is reversible and selective and so safer.
- Why they take weeks to work is worth a sentence: reuptake blockade is immediate, but the clinical effect requires adaptive changes, including autoreceptor desensitisation, altered receptor expression and neuroplastic change. This also explains why the early period carries risk, as energy and agitation may improve before mood does.
Lithium
- Mechanism: not a receptor drug. Lithium substitutes for sodium in excitable tissue and alters intracellular signalling, inhibiting inositol monophosphatase and glycogen synthase kinase 3, damping second messenger systems and producing neurotrophic effects. It is effective in mania and prophylaxis of bipolar disorder and reduces suicide risk.
- Kinetics explain nearly all the problems: complete oral absorption, no protein binding, no metabolism, and entirely renal excretion, handled like sodium in the proximal tubule. It has a narrow therapeutic index, so monitoring is routine; concentrations are interpreted against the timing of the last dose, and specific target ranges should be taken from the Australian Medicines Handbook or local guidelines.
- Anything that makes the kidney retain sodium makes it retain lithium: volume depletion from vomiting, diarrhoea, sweating or poor intake; thiazide diuretics; non-steroidal anti-inflammatory drugs; angiotensin converting enzyme inhibitors and receptor blockers; and acute kidney injury of any cause. This is the commonest route to toxicity, and it means an intercurrent illness is enough to tip a stable patient over.
- Chronic adverse effects: fine tremor, polyuria and polydipsia from nephrogenic diabetes insipidus (lithium interferes with vasopressin signalling in the collecting duct), hypothyroidism and sometimes hyperthyroidism, hypercalcaemia from hyperparathyroidism, weight gain, acne and psoriasis, chronic interstitial nephropathy, T wave flattening, and teratogenicity.
- Toxicity is predominantly neurological, which distinguishes it from most other drug toxicity: coarse tremor, hyperreflexia, ataxia, dysarthria, agitation, myoclonus, seizures and encephalopathy, with nausea and diarrhoea. Gradations matter: an acute overdose in a lithium-naive patient is mainly gastrointestinal with a high concentration and relatively few neurological signs, whereas chronic toxicity produces severe neurological features at a far lower concentration, because the drug has equilibrated into the brain. Because lithium has a small volume of distribution, no protein binding and low molecular weight, it is dialysable, which is the specific intervention in severe toxicity; activated charcoal does not bind it. Treatment otherwise rests on stopping the drug, correcting volume and sodium deficits to restore renal clearance, and monitoring; a syndrome of irreversible lithium-effectuated neurotoxicity can persist after recovery.
Telling the hyperthermic syndromes apart
Three drug-induced syndromes share fever, altered mental state and neuromuscular signs, and they are distinguished by mechanism, onset and the character of the neuromuscular findings.
Neuroleptic malignant syndrome follows dopamine blockade (or abrupt withdrawal of a dopamine agonist in parkinsonism). Onset is over days, and the picture is lead-pipe rigidity, hyperthermia, autonomic instability, altered consciousness, a very high creatine kinase and a risk of rhabdomyolysis and renal failure. Reflexes are normal or reduced. Treatment is supportive with cooling and cessation of the drug, with dantrolene (inhibiting sarcoplasmic calcium release) and dopamine agonists used in severe cases.
Serotonin toxicity follows excess serotonergic activity, usually from a combination of drugs. Onset is within hours, and the characteristic findings are clonus (inducible, spontaneous or ocular), hyperreflexia, tremor, agitation, diaphoresis, mydriasis, hyperactive bowel sounds and hyperthermia in severe cases. The lower limbs are affected more than the upper. Treatment is to stop the drugs, cool, sedate generously with benzodiazepines, and consider cyproheptadine as a 5-HT2A antagonist.
Anticholinergic toxicity gives hyperthermia with dry skin, flushing, mydriasis, urinary retention, absent bowel sounds and delirium, and normal reflexes: the dry skin and quiet abdomen are the discriminators, since both of the others are sweaty with increased bowel activity.
For completeness, malignant hyperthermia is triggered by volatile agents and suxamethonium through the ryanodine receptor, with rigidity and a rapidly rising carbon dioxide under anaesthesia; sympathomimetic toxicity gives agitation, hypertension, tachycardia and sweating without rigidity; and thyroid storm and withdrawal states are the non-drug mimics to keep in mind.
Making the answer flow
- Begin with the receptor profile, then derive the adverse effects; this works for every agent in the group and sounds like understanding rather than lists.
- Use the four dopamine pathways to explain why one receptor produces four different consequences.
- For lithium, lead with the kinetics: no metabolism, renal clearance like sodium, narrow margin. Every interaction follows.
- Separate the hyperthermic syndromes by onset and neuromuscular signs, not by the drug alone.
Where marks are lost
- Mistaking akathisia for worsening psychosis and increasing the drug.
- Saying atypical agents have no extrapyramidal effects, rather than fewer.
- Forgetting that metoclopramide and prochlorperazine cause dystonia by the same mechanism.
- Interpreting a lithium concentration without asking whether the toxicity is acute or chronic.
- Confusing neuroleptic malignant syndrome with serotonin toxicity: rigidity over days against clonus within hours.
Where this meets intensive care
- Antipsychotics used for delirium block dopamine D2 receptors and many prolong the QT interval; check the ECG and electrolytes.
- Serotonin toxicity can follow combinations such as fentanyl, tramadol or linezolid with a serotonergic antidepressant; clonus and hyperreflexia are the clues.
Viva questions
Answer each one aloud, as you would to an examiner, before you open the model points.
- 1.
How do antipsychotic drugs work, and why do they cause so many adverse effects?
Show answer
- D2 blockade in the mesolimbic pathway gives the antipsychotic effect.
- The same blockade in the nigrostriatal pathway causes extrapyramidal effects, in the tuberoinfundibular pathway raises prolactin, and in the mesocortical pathway may worsen negative symptoms.
- Additional receptor actions explain the rest: H1 and 5-HT2C for weight gain and sedation, muscarinic for anticholinergic effects, alpha-1 for postural hypotension.
- Atypicals add 5-HT2A blockade and bind D2 more loosely, trading extrapyramidal for metabolic effects.
- 2.
Describe the extrapyramidal syndromes and their time courses.
Show answer
- Acute dystonia within hours to days; treated with an antimuscarinic; laryngeal involvement is dangerous.
- Akathisia within days to weeks; inner restlessness, easily mistaken for agitation.
- Parkinsonism over weeks; bradykinesia, rigidity, tremor.
- Tardive dyskinesia after months to years; may be irreversible and can worsen on withdrawal.
- 3.
What makes clozapine different?
Show answer
- Reserved for treatment-resistant schizophrenia; low extrapyramidal risk and little prolactin elevation.
- Agranulocytosis requiring mandatory blood count monitoring.
- Myocarditis and cardiomyopathy, seizures at higher exposure, severe constipation with ileus, hypersalivation.
- Marked metabolic effects; smoking induces its metabolism, so levels rise when a patient stops smoking.
- 4.
Classify the antidepressants by mechanism.
Show answer
- Selective serotonin reuptake inhibitors: serotonin transporter blockade.
- Serotonin and noradrenaline reuptake inhibitors: both transporters.
- Tricyclics: reuptake inhibition plus muscarinic, H1, alpha-1 and cardiac sodium and potassium channel blockade.
- Monoamine oxidase inhibitors: prevent monoamine breakdown; mirtazapine: presynaptic alpha-2 and 5-HT2 and H1 blockade.
- Clinical effect takes weeks because it depends on adaptive receptor and neuroplastic change, not on reuptake blockade alone.
- 5.
Why are tricyclic antidepressants dangerous in overdose?
Show answer
- Cardiac sodium channel blockade causes QRS widening, conduction delay and ventricular arrhythmia.
- Potassium channel blockade prolongs the QT interval.
- Alpha-1 blockade causes vasodilatation and hypotension; anticholinergic effects cause delirium, retention and tachycardia.
- Central effects cause seizures, which worsen acidosis and so worsen sodium channel blockade.
- Sodium bicarbonate is used for the sodium channel effects; follow local toxicology guidance.
- 6.
Describe the pharmacology of lithium.
Show answer
- Alters intracellular signalling through inositol monophosphatase and glycogen synthase kinase 3 inhibition rather than acting at a receptor.
- Complete absorption, no protein binding, no metabolism, entirely renal excretion handled like sodium.
- Narrow therapeutic index requiring monitoring, with concentrations interpreted against the timing of the last dose.
- Chronic effects: tremor, nephrogenic diabetes insipidus, thyroid dysfunction, hypercalcaemia, interstitial nephropathy, teratogenicity.
- 7.
Why might a stable patient on lithium become toxic?
Show answer
- Anything reducing renal sodium and water excretion reduces lithium clearance.
- Volume depletion from vomiting, diarrhoea, sweating or poor intake; intercurrent illness.
- Drugs: thiazides, non-steroidal anti-inflammatory drugs, angiotensin converting enzyme inhibitors and receptor blockers.
- Acute kidney injury of any cause; lithium-induced diabetes insipidus makes dehydration more likely.
- 8.
How do you distinguish neuroleptic malignant syndrome from serotonin toxicity?
Show answer
- Neuroleptic malignant syndrome: dopamine blockade or dopamine agonist withdrawal; onset over days; lead-pipe rigidity, normal or reduced reflexes, very high creatine kinase.
- Serotonin toxicity: serotonergic excess, usually a drug combination; onset within hours; clonus and hyperreflexia, lower limbs more than upper, hyperactive bowel sounds, mydriasis.
- Both have hyperthermia, autonomic instability and altered mental state.
- Anticholinergic toxicity is the third mimic, with dry skin and absent bowel sounds.
- Treatment of both rests on stopping the drug, cooling and supportive care, with dantrolene or cyproheptadine respectively in severe cases.
Practise this week
- First Part MCQs: pharmacology
- First Part SAQs, marked part by part
- First Part cross-table vivas
- Viva Examiner: practise answering aloud
Week 16 in the other subjects
Not affiliated with the CICM. Notes are a revision aid, not a substitute for the curriculum or for clinical guidelines.